JP2018531005A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531005A5 JP2018531005A5 JP2018515130A JP2018515130A JP2018531005A5 JP 2018531005 A5 JP2018531005 A5 JP 2018531005A5 JP 2018515130 A JP2018515130 A JP 2018515130A JP 2018515130 A JP2018515130 A JP 2018515130A JP 2018531005 A5 JP2018531005 A5 JP 2018531005A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- optionally
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 124
- 239000003814 drug Substances 0.000 claims 74
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 63
- 208000035475 disorder Diseases 0.000 claims 47
- 229920002674 hyaluronan Polymers 0.000 claims 46
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 45
- 229960003160 hyaluronic acid Drugs 0.000 claims 45
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 41
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 41
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 41
- 208000002780 macular degeneration Diseases 0.000 claims 36
- 206010064930 age-related macular degeneration Diseases 0.000 claims 32
- 229920000642 polymer Polymers 0.000 claims 31
- 108020001507 fusion proteins Proteins 0.000 claims 30
- 102000037865 fusion proteins Human genes 0.000 claims 30
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims 29
- 238000000034 method Methods 0.000 claims 21
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 18
- 201000011190 diabetic macular edema Diseases 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 16
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 16
- 208000015181 infectious disease Diseases 0.000 claims 16
- 230000002458 infectious effect Effects 0.000 claims 16
- 230000004048 modification Effects 0.000 claims 16
- 238000012986 modification Methods 0.000 claims 16
- 208000004644 retinal vein occlusion Diseases 0.000 claims 16
- 108091008605 VEGF receptors Proteins 0.000 claims 15
- 125000000539 amino acid group Chemical group 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 15
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 14
- 108091008601 sVEGFR Proteins 0.000 claims 14
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 13
- 230000002401 inhibitory effect Effects 0.000 claims 13
- 229940079593 drug Drugs 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 11
- 229940127121 immunoconjugate Drugs 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 230000033115 angiogenesis Effects 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 230000008728 vascular permeability Effects 0.000 claims 10
- 206010010741 Conjunctivitis Diseases 0.000 claims 9
- 208000001344 Macular Edema Diseases 0.000 claims 9
- 102000005962 receptors Human genes 0.000 claims 9
- 108020003175 receptors Proteins 0.000 claims 9
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical group COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 claims 8
- 108091023037 Aptamer Proteins 0.000 claims 8
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 8
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims 8
- 201000002563 Histoplasmosis Diseases 0.000 claims 8
- 101000847156 Homo sapiens Tumor necrosis factor-inducible gene 6 protein Proteins 0.000 claims 8
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 8
- 208000017442 Retinal disease Diseases 0.000 claims 8
- 206010038923 Retinopathy Diseases 0.000 claims 8
- 206010046851 Uveitis Diseases 0.000 claims 8
- 108010081667 aflibercept Proteins 0.000 claims 8
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 8
- 239000005557 antagonist Substances 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 201000000159 corneal neovascularization Diseases 0.000 claims 8
- 208000030533 eye disease Diseases 0.000 claims 8
- 102000050255 human TNFAIP6 Human genes 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 230000002062 proliferating effect Effects 0.000 claims 8
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims 7
- 229940123429 VEGFR tyrosine kinase inhibitor Drugs 0.000 claims 7
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 7
- 230000002207 retinal effect Effects 0.000 claims 7
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 6
- 102000003816 Interleukin-13 Human genes 0.000 claims 6
- 108090000176 Interleukin-13 Proteins 0.000 claims 6
- 102000004559 Interleukin-13 Receptors Human genes 0.000 claims 6
- 108010017511 Interleukin-13 Receptors Proteins 0.000 claims 6
- 102000004889 Interleukin-6 Human genes 0.000 claims 6
- 108090001005 Interleukin-6 Proteins 0.000 claims 6
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 6
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 6
- 102000004890 Interleukin-8 Human genes 0.000 claims 6
- 108090001007 Interleukin-8 Proteins 0.000 claims 6
- 208000022873 Ocular disease Diseases 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 239000003889 eye drop Substances 0.000 claims 6
- 229940012356 eye drops Drugs 0.000 claims 6
- 102000058223 human VEGFA Human genes 0.000 claims 6
- 238000001802 infusion Methods 0.000 claims 6
- 239000007924 injection Substances 0.000 claims 6
- 238000002347 injection Methods 0.000 claims 6
- 229940100601 interleukin-6 Drugs 0.000 claims 6
- 229940096397 interleukin-8 Drugs 0.000 claims 6
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims 6
- 108091008602 mbVEGFR Proteins 0.000 claims 6
- 210000003786 sclera Anatomy 0.000 claims 6
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 6
- -1 4-bromo-2-fluoroanilino Chemical group 0.000 claims 5
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 claims 5
- 102100038568 Age-related maculopathy susceptibility protein 2 Human genes 0.000 claims 5
- 102100034608 Angiopoietin-2 Human genes 0.000 claims 5
- 108010048036 Angiopoietin-2 Proteins 0.000 claims 5
- 102000009840 Angiopoietins Human genes 0.000 claims 5
- 108010009906 Angiopoietins Proteins 0.000 claims 5
- 102000018746 Apelin Human genes 0.000 claims 5
- 108010052412 Apelin Proteins 0.000 claims 5
- 101800001382 Betacellulin Proteins 0.000 claims 5
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 claims 5
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 claims 5
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 claims 5
- 108020004705 Codon Proteins 0.000 claims 5
- 102100036217 Collagen alpha-1(X) chain Human genes 0.000 claims 5
- 102000003712 Complement factor B Human genes 0.000 claims 5
- 108090000056 Complement factor B Proteins 0.000 claims 5
- 102100035321 Complement factor H-related protein 3 Human genes 0.000 claims 5
- 206010058202 Cystoid macular oedema Diseases 0.000 claims 5
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 5
- 102000003951 Erythropoietin Human genes 0.000 claims 5
- 108090000394 Erythropoietin Proteins 0.000 claims 5
- 208000028506 Familial Exudative Vitreoretinopathies Diseases 0.000 claims 5
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 claims 5
- 101000808726 Homo sapiens Age-related maculopathy susceptibility protein 2 Proteins 0.000 claims 5
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 claims 5
- 101000875027 Homo sapiens Collagen alpha-1(X) chain Proteins 0.000 claims 5
- 101000878136 Homo sapiens Complement factor H-related protein 3 Proteins 0.000 claims 5
- 101000941289 Homo sapiens Hepatic triacylglycerol lipase Proteins 0.000 claims 5
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims 5
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 5
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 5
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 5
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 claims 5
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 claims 5
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims 5
- 102100029837 Probetacellulin Human genes 0.000 claims 5
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 5
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 5
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 5
- 108091007178 TNFRSF10A Proteins 0.000 claims 5
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 claims 5
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims 5
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 5
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims 5
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 5
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 5
- BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 claims 5
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 5
- 210000003161 choroid Anatomy 0.000 claims 5
- 230000024203 complement activation Effects 0.000 claims 5
- 201000010206 cystoid macular edema Diseases 0.000 claims 5
- 229940105423 erythropoietin Drugs 0.000 claims 5
- 201000006902 exudative vitreoretinopathy Diseases 0.000 claims 5
- 102000006495 integrins Human genes 0.000 claims 5
- 108010044426 integrins Proteins 0.000 claims 5
- 201000001937 osteoporosis-pseudoglioma syndrome Diseases 0.000 claims 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 5
- 206010007747 Cataract congenital Diseases 0.000 claims 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 4
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 4
- 208000021089 Coats disease Diseases 0.000 claims 4
- 102100022133 Complement C3 Human genes 0.000 claims 4
- 102000016550 Complement Factor H Human genes 0.000 claims 4
- 108010053085 Complement Factor H Proteins 0.000 claims 4
- 102000003706 Complement factor D Human genes 0.000 claims 4
- 108090000059 Complement factor D Proteins 0.000 claims 4
- 206010010719 Conjunctival haemorrhage Diseases 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 4
- 206010013774 Dry eye Diseases 0.000 claims 4
- 208000010412 Glaucoma Diseases 0.000 claims 4
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- 206010025415 Macular oedema Diseases 0.000 claims 4
- 206010029113 Neovascularisation Diseases 0.000 claims 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 4
- 201000010183 Papilledema Diseases 0.000 claims 4
- 208000008709 Retinal Telangiectasis Diseases 0.000 claims 4
- 201000007737 Retinal degeneration Diseases 0.000 claims 4
- 206010038910 Retinitis Diseases 0.000 claims 4
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 4
- 206010043189 Telangiectasia Diseases 0.000 claims 4
- 229960002833 aflibercept Drugs 0.000 claims 4
- 230000000172 allergic effect Effects 0.000 claims 4
- 208000010668 atopic eczema Diseases 0.000 claims 4
- 208000010217 blepharitis Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229960002412 cediranib Drugs 0.000 claims 4
- 239000003246 corticosteroid Substances 0.000 claims 4
- 239000000430 cytokine receptor antagonist Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 208000001309 degenerative myopia Diseases 0.000 claims 4
- 230000004340 degenerative myopia Effects 0.000 claims 4
- 229940051306 eylea Drugs 0.000 claims 4
- 238000011010 flushing procedure Methods 0.000 claims 4
- 239000000017 hydrogel Substances 0.000 claims 4
- 229920001477 hydrophilic polymer Polymers 0.000 claims 4
- 201000001948 hypertensive retinopathy Diseases 0.000 claims 4
- 239000007943 implant Substances 0.000 claims 4
- 208000028867 ischemia Diseases 0.000 claims 4
- 229940076783 lucentis Drugs 0.000 claims 4
- 229940092110 macugen Drugs 0.000 claims 4
- 201000010230 macular retinal edema Diseases 0.000 claims 4
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 claims 4
- 201000003142 neovascular glaucoma Diseases 0.000 claims 4
- 229960003407 pegaptanib Drugs 0.000 claims 4
- 229960003876 ranibizumab Drugs 0.000 claims 4
- 230000004258 retinal degeneration Effects 0.000 claims 4
- 238000012163 sequencing technique Methods 0.000 claims 4
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 4
- 229960001796 sunitinib Drugs 0.000 claims 4
- 229940034785 sutent Drugs 0.000 claims 4
- 208000009056 telangiectasis Diseases 0.000 claims 4
- 230000000472 traumatic effect Effects 0.000 claims 4
- 229950000578 vatalanib Drugs 0.000 claims 4
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims 4
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 206010065630 Iris neovascularisation Diseases 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 229920000954 Polyglycolide Polymers 0.000 claims 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 210000000683 abdominal cavity Anatomy 0.000 claims 3
- 230000000202 analgesic effect Effects 0.000 claims 3
- 102000023732 binding proteins Human genes 0.000 claims 3
- 108091008324 binding proteins Proteins 0.000 claims 3
- 210000004204 blood vessel Anatomy 0.000 claims 3
- 210000000795 conjunctiva Anatomy 0.000 claims 3
- 239000006071 cream Substances 0.000 claims 3
- 231100000040 eye damage Toxicity 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 238000001361 intraarterial administration Methods 0.000 claims 3
- 238000007917 intracranial administration Methods 0.000 claims 3
- 238000007912 intraperitoneal administration Methods 0.000 claims 3
- 210000004877 mucosa Anatomy 0.000 claims 3
- 230000009826 neoplastic cell growth Effects 0.000 claims 3
- 239000002674 ointment Substances 0.000 claims 3
- 230000010412 perfusion Effects 0.000 claims 3
- 210000003516 pericardium Anatomy 0.000 claims 3
- 210000004303 peritoneum Anatomy 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 239000004633 polyglycolic acid Substances 0.000 claims 3
- 239000002243 precursor Substances 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- 210000000664 rectum Anatomy 0.000 claims 3
- 210000001210 retinal vessel Anatomy 0.000 claims 3
- 210000001215 vagina Anatomy 0.000 claims 3
- 230000002792 vascular Effects 0.000 claims 3
- 238000005406 washing Methods 0.000 claims 3
- 206010003445 Ascites Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000002691 Choroiditis Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 108010038807 Oligopeptides Proteins 0.000 claims 2
- 102000015636 Oligopeptides Human genes 0.000 claims 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000005228 Pericardial Effusion Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000002151 Pleural effusion Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 208000003971 Posterior uveitis Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 2
- 230000003474 anti-emetic effect Effects 0.000 claims 2
- 239000002111 antiemetic agent Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940022399 cancer vaccine Drugs 0.000 claims 2
- 238000009566 cancer vaccine Methods 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 238000012350 deep sequencing Methods 0.000 claims 2
- 239000003966 growth inhibitor Substances 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 210000004912 pericardial fluid Anatomy 0.000 claims 2
- 238000002823 phage display Methods 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100036601 Aggrecan core protein Human genes 0.000 claims 1
- 108010067219 Aggrecans Proteins 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims 1
- 108010044213 Class 5 Receptor-Like Protein Tyrosine Phosphatases Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 208000034508 Haemangioma of retina Diseases 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 101001078445 Homo sapiens Hyaluronan and proteoglycan link protein 2 Proteins 0.000 claims 1
- 101001078431 Homo sapiens Hyaluronan and proteoglycan link protein 3 Proteins 0.000 claims 1
- 101001078435 Homo sapiens Hyaluronan and proteoglycan link protein 4 Proteins 0.000 claims 1
- 108010013214 Hyaluronan Receptors Proteins 0.000 claims 1
- 102000018866 Hyaluronan Receptors Human genes 0.000 claims 1
- 102100028084 Hyaluronan and proteoglycan link protein 1 Human genes 0.000 claims 1
- 101710191341 Hyaluronan and proteoglycan link protein 1 Proteins 0.000 claims 1
- 102100025264 Hyaluronan and proteoglycan link protein 2 Human genes 0.000 claims 1
- 102100025260 Hyaluronan and proteoglycan link protein 3 Human genes 0.000 claims 1
- 102100025266 Hyaluronan and proteoglycan link protein 4 Human genes 0.000 claims 1
- 102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 claims 1
- 101710178181 Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 claims 1
- 108010043296 Neurocan Proteins 0.000 claims 1
- 102100030466 Neurocan core protein Human genes 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims 1
- 102100028508 Receptor-type tyrosine-protein phosphatase zeta Human genes 0.000 claims 1
- 102100024471 Stabilin-1 Human genes 0.000 claims 1
- 101710164042 Stabilin-1 Proteins 0.000 claims 1
- 102100024470 Stabilin-2 Human genes 0.000 claims 1
- 101710164033 Stabilin-2 Proteins 0.000 claims 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 238000002819 bacterial display Methods 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims 1
- 229940099552 hyaluronan Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000001926 lymphatic effect Effects 0.000 claims 1
- 238000002824 mRNA display Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 238000007481 next generation sequencing Methods 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 238000002818 protein evolution Methods 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 238000002702 ribosome display Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021166061A JP2022017288A (ja) | 2015-09-23 | 2021-10-08 | 抗ｖｅｇｆ抗体の最適化変異体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562222698P | 2015-09-23 | 2015-09-23 | |
| US62/222,698 | 2015-09-23 | ||
| US201562271913P | 2015-12-28 | 2015-12-28 | |
| US62/271,913 | 2015-12-28 | ||
| PCT/US2016/053454 WO2017053807A2 (en) | 2015-09-23 | 2016-09-23 | Optimized variants of anti-vegf antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021166061A Division JP2022017288A (ja) | 2015-09-23 | 2021-10-08 | 抗ｖｅｇｆ抗体の最適化変異体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018531005A JP2018531005A (ja) | 2018-10-25 |
| JP2018531005A6 JP2018531005A6 (ja) | 2018-12-13 |
| JP2018531005A5 true JP2018531005A5 (enExample) | 2019-11-07 |
| JP6959912B2 JP6959912B2 (ja) | 2021-11-05 |
Family
ID=57043061
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515130A Active JP6959912B2 (ja) | 2015-09-23 | 2016-09-23 | 抗ｖｅｇｆ抗体の最適化変異体 |
| JP2021166061A Pending JP2022017288A (ja) | 2015-09-23 | 2021-10-08 | 抗ｖｅｇｆ抗体の最適化変異体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021166061A Pending JP2022017288A (ja) | 2015-09-23 | 2021-10-08 | 抗ｖｅｇｆ抗体の最適化変異体 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US10072075B2 (enExample) |
| EP (1) | EP3353203A2 (enExample) |
| JP (2) | JP6959912B2 (enExample) |
| KR (1) | KR102725051B1 (enExample) |
| CN (2) | CN116987187A (enExample) |
| AU (1) | AU2016326666B2 (enExample) |
| CA (1) | CA2992602A1 (enExample) |
| CL (2) | CL2018000732A1 (enExample) |
| CO (1) | CO2018003863A2 (enExample) |
| CR (1) | CR20180221A (enExample) |
| IL (1) | IL257565B2 (enExample) |
| MA (1) | MA42924A (enExample) |
| MX (1) | MX2018003537A (enExample) |
| MY (1) | MY191756A (enExample) |
| PE (1) | PE20181363A1 (enExample) |
| PH (1) | PH12018500657A1 (enExample) |
| RU (1) | RU2763916C2 (enExample) |
| SG (1) | SG10201911226QA (enExample) |
| TW (1) | TWI748962B (enExample) |
| UA (1) | UA125432C2 (enExample) |
| WO (1) | WO2017053807A2 (enExample) |
| ZA (1) | ZA201800770B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007237096C1 (en) | 2006-04-07 | 2012-12-13 | EyePoint Pharmaceuticals, Inc. | Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof |
| EP2268673B1 (en) | 2008-03-28 | 2017-10-25 | The Regents of The University of California | Polypeptide-polymer conjugates and methods of use thereof |
| EP3505182A1 (en) | 2011-10-13 | 2019-07-03 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| SG10201911226QA (en) | 2015-09-23 | 2020-01-30 | Genentech Inc | Optimized variants of anti-vegf antibodies |
| WO2017075189A1 (en) * | 2015-10-27 | 2017-05-04 | University Of Massachusetts | Factor h-fc immunotherapy |
| CN113546178A (zh) | 2015-12-09 | 2021-10-26 | 加利福尼亚大学董事会 | 治疗眼部疾病或病症的方法 |
| CA3010056A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| KR20240052871A (ko) | 2016-04-27 | 2024-04-23 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| WO2018017714A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| CN110891611B (zh) | 2017-03-22 | 2024-03-29 | 阿森迪斯制药公司 | 水凝胶交联透明质酸前药组合物和方法 |
| JP7227151B2 (ja) * | 2017-03-22 | 2023-02-21 | ジェネンテック， インコーポレイテッド | 眼障害の治療のために最適化された抗体組成物 |
| JP7161494B2 (ja) * | 2017-05-06 | 2022-10-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｐｌｎｒアンタゴニストおよびｖｅｇｆ阻害剤によって眼疾患を治療する方法 |
| CN110582294A (zh) | 2017-05-26 | 2019-12-17 | S·惠特卡普 | 一种用于治疗酒渣鼻的外用组合物及用其治疗酒渣鼻的方法 |
| CN110959012A (zh) * | 2017-06-05 | 2020-04-03 | 詹森生物科技公司 | 工程化表面电荷用于产生双特异性抗体的方法 |
| WO2019094387A1 (en) * | 2017-11-08 | 2019-05-16 | The Regents Of The University Of Colorado, A Body Corporate | Hydrogel drug delivery systems for the treatment of pediatric growth plate injuries |
| EP4609914A3 (en) | 2017-11-30 | 2025-10-15 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist to treat angiogenic eye disorders |
| JP7436365B2 (ja) * | 2017-12-29 | 2024-02-21 | エフ． ホフマン－ラ ロシュ アーゲー | 抗ｖｅｇｆ抗体及び使用の方法 |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| CN111867631A (zh) * | 2018-03-16 | 2020-10-30 | 诺华股份有限公司 | 治疗眼部疾病的方法 |
| TWI813649B (zh) * | 2018-03-20 | 2023-09-01 | 財團法人國家衛生研究院 | 可標靶ｖｅｇｆｒ２與ｖｅｇｆｒ３的雙功能抗體 |
| CN108752473B (zh) * | 2018-05-03 | 2021-08-31 | 陕西师范大学 | 一种抗c5全人源单链抗体c5b3及其应用 |
| IL318714A (en) | 2018-05-10 | 2025-03-01 | Regeneron Pharma | Formulations that include high concentrations of VEGF receptor fusion protein |
| EP3856245A4 (en) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF |
| WO2020064847A1 (en) | 2018-09-26 | 2020-04-02 | Ascendis Pharma A/S | Degradable hyaluronic acid hydrogels |
| EP3898669A1 (en) * | 2018-12-21 | 2021-10-27 | F. Hoffmann-La Roche AG | Method for improving inhibition of vegf-binding to vegf-r1 of an anti-vegf antibody |
| EP3931375A4 (en) * | 2019-03-01 | 2022-12-07 | Fred Hutchinson Cancer Center | Protein residue mapping using a combination of deep mutational scanning and phage display high throughput sequencing |
| CN109942685A (zh) * | 2019-03-13 | 2019-06-28 | 中山大学附属第五医院 | 应用细菌展示文库筛选特异结合ddx24解旋酶的多肽 |
| US20220227855A1 (en) * | 2019-04-25 | 2022-07-21 | The University Of Massachusetts | Compositions and methods for treatment of angiogenesis related diseases |
| WO2021013065A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 人源化抗VEGF Fab抗体片段及其用途 |
| CN114786731A (zh) * | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| KR102390931B1 (ko) * | 2020-02-07 | 2022-04-26 | 한국과학기술원 | 보체 단백 분해 산물 C3a와 결합할 수 있는 신규한 폴리펩타이드 및 이의 용도 |
| JP7667797B2 (ja) * | 2020-04-10 | 2025-04-23 | ベラバス， インコーポレイテッド | 分析的および治療的使用のための抗原特異的抗体の富化 |
| AU2021308712B2 (en) * | 2020-07-16 | 2025-10-09 | Novartis Ag | Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| CN112137961A (zh) * | 2020-09-30 | 2020-12-29 | 严鹏科 | 一种雷帕霉素组合物及其制备方法 |
| WO2022086501A1 (en) * | 2020-10-20 | 2022-04-28 | The Scripps Research Institute | Methods and compositions for treating ocular vascular disorders |
| CN117043186A (zh) * | 2020-10-21 | 2023-11-10 | 勃林格殷格翰国际有限公司 | 用于治疗眼部疾病的激动性TrkB结合分子 |
| CA3211803A1 (en) * | 2021-02-27 | 2022-09-01 | Eluminex Biosciences (Suzhou) Limited | Antibody fusion proteins targeting il-6 receptor and angiogenic factors |
| CN116059312A (zh) * | 2021-07-23 | 2023-05-05 | 百奥泰生物制药股份有限公司 | 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用 |
| CU24770B1 (es) * | 2021-12-15 | 2025-09-01 | Ct Ingenieria Genetica Biotecnologia | Polipéptidos que se unen al factor de crecimiento del endotelio vascular y al factor básico de crecimiento de fibroblastos |
| KR20240142564A (ko) * | 2022-02-10 | 2024-09-30 | 코디악 사이언시스 인코포레이티드 | 생산물 정제 방법 |
| CA3246703A1 (en) * | 2022-03-26 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV-1 BISPECIFIC ENVELOPE ANTIBODIES AND THEIR USE |
| EP4514845A1 (en) | 2022-04-29 | 2025-03-05 | Broadwing Bio LLC | Bispecific antibodies and methods of treating ocular disease |
| WO2023245187A2 (en) | 2022-06-17 | 2023-12-21 | Apogee Biologics, Inc. | Antibodies that bind interleukin 13 and methods of use |
| WO2024123791A1 (en) * | 2022-12-05 | 2024-06-13 | Kodiak Sciences Inc. | Formulations for dual vegf/il-6 inhibitors |
| WO2025054768A1 (en) * | 2023-09-11 | 2025-03-20 | Eluminex Biosciences (Suzhou) Limited | Multispecific fusion proteins targeting angiogenic and inflammatory factors |
Family Cites Families (186)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| FR2596047B1 (fr) | 1986-03-21 | 1988-05-13 | Charbonnages Ste Chimique | Procede de production de styrene |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5688666A (en) | 1988-10-28 | 1997-11-18 | Genentech, Inc. | Growth hormone variants with altered binding properties |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| US5144088A (en) | 1991-04-26 | 1992-09-01 | Aristech Chemical Corporation | Manufacture of neopentyl glycol (I) |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
| JPH08500962A (ja) | 1992-02-06 | 1996-02-06 | クリエイティブ バイオモレキュルズ，インコーポレイテッド | 癌マーカー用生物合成結合蛋白質 |
| DE69333823T2 (de) | 1992-03-24 | 2006-05-04 | Cambridge Antibody Technology Ltd., Melbourn | Verfahren zur herstellung von gliedern von spezifischen bindungspaaren |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5872094A (en) | 1993-01-06 | 1999-02-16 | The General Hospital Corporation | Method for attaching cartilaginous tissue, cartilage matrix protein or link protein to a surface |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5675063A (en) | 1995-02-28 | 1997-10-07 | Loyola University Of Chicago | Immortalized rabbit hybridoma fusion partner |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| ATE214075T1 (de) | 1996-05-31 | 2002-03-15 | Health Research Inc | Monoklonale antikörper gegen endoglin und ihre verwendung in der anti-angiogenese-therapie |
| DK1325932T5 (da) | 1997-04-07 | 2005-10-03 | Genentech Inc | Anti-VEGF antistoffer |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US20070059302A1 (en) | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
| CA2205771C (en) | 1997-05-22 | 2002-05-14 | Hyal Pharmaceutical Corporation | Improved delivery of disease modifiers |
| AU7704498A (en) | 1997-05-29 | 1998-12-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Human frp and fragments thereof including methods for using them |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| WO2000034337A1 (en) | 1998-12-10 | 2000-06-15 | Tsukuba Research Laboratory, Toagosei Co., Ltd. | Humanized monoclonal antibodies against vascular endothelial cell growth factor |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR101155191B1 (ko) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| CA2372053C (en) | 1999-04-28 | 2008-09-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| ATE315789T1 (de) | 1999-11-16 | 2006-02-15 | Genentech Inc | Elisa für vegf |
| US20030180714A1 (en) | 1999-12-15 | 2003-09-25 | Genentech, Inc. | Shotgun scanning |
| PT1242438E (pt) | 1999-12-29 | 2007-02-28 | Immunogen Inc | Agentes citotóxicos compreendendo dixorrubicinas e daunorrubicinas modificadas e seu uso terapêutico |
| CN1299833A (zh) | 1999-12-30 | 2001-06-20 | 华西医科大学口腔医学研究所 | 抗人血管内皮生长因子单链抗体及其制备方法 |
| SI2857516T1 (sl) | 2000-04-11 | 2017-09-29 | Genentech, Inc. | Multivalentna protitelesa in njihove uporabe |
| EP1331266B1 (en) | 2000-10-06 | 2017-01-04 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
| US20030176674A1 (en) | 2001-04-13 | 2003-09-18 | Rosen Craig A. | Vascular endothelial growth factor 2 |
| JP2004536579A (ja) | 2001-04-13 | 2004-12-09 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 血管内皮増殖因子２ |
| NZ603111A (en) | 2001-08-03 | 2014-05-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| CN1187373C (zh) | 2002-03-20 | 2005-02-02 | 上海中信国健药业有限公司 | 人源化抗血管内皮生长因子单克隆抗体及其制法和药物组合物 |
| JPWO2003085119A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法 |
| JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
| US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
| EP1500400A4 (en) | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT CONTAINING ANTIBODY COMPOSITION |
| BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
| AU2003236020B2 (en) | 2002-04-09 | 2009-03-19 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in GDP-fucose transport |
| WO2003099999A2 (en) | 2002-05-20 | 2003-12-04 | Abmaxis, Inc. | Generation and selection of protein library in silico |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US8956160B2 (en) | 2002-07-02 | 2015-02-17 | Ranir, Llc | Device and method for delivering an oral care agent |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
| WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| MXPA05012723A (es) | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
| US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| KR20060069825A (ko) | 2003-08-01 | 2006-06-22 | 제넨테크, 인크. | 제한된 다양성을 갖는 항체 ｃｄｒ 폴리펩티드 서열 |
| WO2005044853A2 (en) * | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| EP1688439A4 (en) | 2003-10-08 | 2007-12-19 | Kyowa Hakko Kogyo Kk | COMPOSITION OF CONDENSED PROTEINS |
| US20070134759A1 (en) | 2003-10-09 | 2007-06-14 | Harue Nishiya | Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase |
| JP4653109B2 (ja) | 2003-11-05 | 2011-03-16 | ロシュ グリクアート アクチェンゲゼルシャフト | 高められたＦｃレセプター結合親和性及びエフェクター機能をもつＣＤ２０抗体 |
| SG149815A1 (en) | 2003-11-06 | 2009-02-27 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| KR101245983B1 (ko) | 2004-03-31 | 2013-06-28 | 제넨테크, 인크. | 인간화 항-ｔｇｆ-베타 항체 |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| PL1737891T3 (pl) | 2004-04-13 | 2013-08-30 | Hoffmann La Roche | Przeciwciała przeciw selektynie p |
| WO2005110374A1 (en) | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US7723472B2 (en) | 2005-02-28 | 2010-05-25 | The Regents Of The University Of California | Extracellular matrix binding chimeric proteins and methods of use thereof |
| US20060204548A1 (en) | 2005-03-01 | 2006-09-14 | Allergan, Inc. | Microimplants for ocular administration |
| US8679490B2 (en) | 2005-11-07 | 2014-03-25 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| JP2009508852A (ja) | 2006-01-23 | 2009-03-05 | クワンジュ インスティチュート オブ サイエンス アンド テクノロジー | 薬理活性物質と粘膜粘着性高分子とが共有結合されたコンジュゲート及びこれを用いた薬理活性物質の経粘膜運搬方法 |
| WO2007134050A2 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| ES2399075T3 (es) | 2006-08-30 | 2013-03-25 | Genentech, Inc. | Anticuerpos multiespecíficos |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| TWI580694B (zh) | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-ｖｅｇｆ抗體 |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| MX2010008024A (es) | 2008-02-01 | 2010-12-21 | Ascendis Pharma As | Profarmaco que comprende un enlazador que se puede separar por si mismo. |
| US8093365B2 (en) | 2008-03-03 | 2012-01-10 | New York University | Biocompatible materials containing stable complexes method of TSG-6 and hyaluronan and method of using same |
| EP2268673B1 (en) | 2008-03-28 | 2017-10-25 | The Regents of The University of California | Polypeptide-polymer conjugates and methods of use thereof |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| US8821870B2 (en) | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| CA2734905A1 (en) | 2008-09-03 | 2010-03-11 | Jenny M. Bostrom | Multispecific antibodies |
| WO2010045506A2 (en) | 2008-10-16 | 2010-04-22 | Kathleen Cogan Farinas | Sustained drug delivery system |
| US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| PL2391419T3 (pl) | 2009-01-29 | 2019-12-31 | Forsight Vision4, Inc. | Dostarczanie leku do tylnego odcinka |
| ES2581318T3 (es) * | 2009-07-17 | 2016-09-05 | Bioatla Llc | Selección y evolución simultáneas e integradas de rendimiento y expresión de anticuerpos/proteínas en huéspedes de producción |
| HUE052816T2 (hu) | 2009-07-31 | 2021-05-28 | Ascendis Pharma As | Biológiailag lebontható polietilénglikol bázisú vízoldható hidrogélek |
| TWI506138B (zh) | 2009-08-11 | 2015-11-01 | Academia Sinica | 生產雙硫鍵穩固之單鏈抗體之方法 |
| JP2013508287A (ja) | 2009-10-14 | 2013-03-07 | ヤンセン バイオテツク，インコーポレーテツド | 抗体を親和性成熟する方法 |
| EP2470565A4 (en) * | 2009-10-23 | 2013-12-11 | Garvan Inst Med Res | MODIFIED VARIABLE DOMAIN MOLECULES AND METHODS FOR PRODUCING AND USING THE SAME |
| US20120282211A1 (en) | 2009-11-24 | 2012-11-08 | Carnegie Mellon University | Antibodies and conjugates for modulators of angiogenesis |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| CN105585630B (zh) | 2010-07-29 | 2020-09-15 | Xencor公司 | 具有修改的等电点的抗体 |
| EP2600812B1 (en) | 2010-08-05 | 2021-09-22 | ForSight Vision4, Inc. | Apparatus to treat an eye |
| WO2012019047A2 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision4, Inc. | Subconjunctival implant for posterior segment drug delivery |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US9321844B2 (en) | 2011-08-05 | 2016-04-26 | Genentech, Inc. | Anti-polyubiquitin antibodies |
| EP2755600B1 (en) | 2011-09-16 | 2021-03-17 | ForSight Vision4, Inc. | Fluid exchange apparatus |
| SG11201400815TA (en) | 2011-10-12 | 2014-09-26 | Ascendis Pharma Ophthalmology Division As | Prevention and treatment of ocular conditions |
| JP6162707B2 (ja) | 2011-10-24 | 2017-07-12 | ハロザイム インコーポレイテッド | 抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法 |
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| US10010448B2 (en) | 2012-02-03 | 2018-07-03 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
| UA120029C2 (uk) | 2012-07-13 | 2019-09-25 | Рош Глікарт Аг | Спосіб зниження в'язкості біспецифічного антитіла до vegf/ang-2 та застосування такого антитіла для лікування судинних очних захворювань |
| MY177912A (en) | 2012-10-11 | 2020-09-25 | Ascendis Pharma Ophthalmology Div A/S | Vegf neutralizing prodrugs for the treatment of ocular conditions |
| CN104903349B (zh) | 2012-11-08 | 2018-10-19 | 十一生物治疗股份有限公司 | Il-6拮抗剂及其应用 |
| US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
| TW201427989A (zh) | 2012-12-18 | 2014-07-16 | Novartis Ag | 長效性蛋白質之組合物及方法 |
| CN103204933B (zh) * | 2013-03-08 | 2014-11-05 | 上海赛伦生物技术有限公司 | 一种稳定性高的人源抗vegf抗体及其应用 |
| US10000582B2 (en) | 2013-04-02 | 2018-06-19 | The Regents Of The University Of California | Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof |
| US20160302965A1 (en) | 2013-12-06 | 2016-10-20 | Forsight Vision4, Inc. | Implantable therapeutic devices |
| GB201400994D0 (en) | 2014-01-21 | 2014-03-05 | Ucl Business Plc | Drug delivery system |
| EP3160990A2 (en) | 2014-06-25 | 2017-05-03 | Novartis AG | Compositions and methods for long acting proteins |
| WO2016073157A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Anti-ang2 antibodies and methods of use thereof |
| DK4268843T3 (da) | 2014-11-07 | 2025-11-10 | F Hoffmann La Roche Ltd | Forbedrede IL-6-antistoffer |
| EA201791029A1 (ru) | 2014-11-10 | 2017-12-29 | Дженентек, Инк. | Антитела против интерлейкина-33 и их применение |
| WO2016081639A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Antibodies against bace1 and use thereof for neural disease immunotherapy |
| CN107531789B (zh) | 2015-04-14 | 2021-08-10 | 中央研究院 | 用于抗血管新生和标靶癌症治疗的抗vegfr2人类抗体 |
| SG10201911226QA (en) | 2015-09-23 | 2020-01-30 | Genentech Inc | Optimized variants of anti-vegf antibodies |
| CN113546178A (zh) | 2015-12-09 | 2021-10-26 | 加利福尼亚大学董事会 | 治疗眼部疾病或病症的方法 |
-
2016
- 2016-09-23 SG SG10201911226QA patent/SG10201911226QA/en unknown
- 2016-09-23 UA UAA201800443A patent/UA125432C2/uk unknown
- 2016-09-23 IL IL257565A patent/IL257565B2/en unknown
- 2016-09-23 AU AU2016326666A patent/AU2016326666B2/en active Active
- 2016-09-23 CA CA2992602A patent/CA2992602A1/en active Pending
- 2016-09-23 TW TW105130888A patent/TWI748962B/zh active
- 2016-09-23 MX MX2018003537A patent/MX2018003537A/es unknown
- 2016-09-23 PE PE2018000425A patent/PE20181363A1/es unknown
- 2016-09-23 JP JP2018515130A patent/JP6959912B2/ja active Active
- 2016-09-23 US US15/274,612 patent/US10072075B2/en active Active
- 2016-09-23 MA MA042924A patent/MA42924A/fr unknown
- 2016-09-23 MY MYPI2018000426A patent/MY191756A/en unknown
- 2016-09-23 CN CN202310807556.0A patent/CN116987187A/zh active Pending
- 2016-09-23 RU RU2018114723A patent/RU2763916C2/ru active
- 2016-09-23 WO PCT/US2016/053454 patent/WO2017053807A2/en not_active Ceased
- 2016-09-23 KR KR1020187008132A patent/KR102725051B1/ko active Active
- 2016-09-23 CN CN201680054735.XA patent/CN108137681B/zh active Active
- 2016-09-23 EP EP16774827.6A patent/EP3353203A2/en active Pending
- 2016-09-26 CR CR20180221A patent/CR20180221A/es unknown
-
2018
- 2018-02-06 ZA ZA2018/00770A patent/ZA201800770B/en unknown
- 2018-03-20 CL CL2018000732A patent/CL2018000732A1/es unknown
- 2018-03-23 PH PH12018500657A patent/PH12018500657A1/en unknown
- 2018-04-11 CO CONC2018/0003863A patent/CO2018003863A2/es unknown
- 2018-07-12 US US16/033,499 patent/US10899828B2/en active Active
- 2018-07-12 US US16/033,353 patent/US10906968B2/en active Active
-
2020
- 2020-12-21 US US17/129,251 patent/US12121586B2/en active Active
-
2021
- 2021-03-02 CL CL2021000519A patent/CL2021000519A1/es unknown
- 2021-10-08 JP JP2021166061A patent/JP2022017288A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531005A5 (enExample) | ||
| RU2018114723A (ru) | Оптимизированные варианты анти-vegf антител | |
| JP2020514376A5 (enExample) | ||
| US12398204B2 (en) | Method of treating an ocular condition by administering multispecific antibodies that activates TIE2 and binds a receptor tyrosine kinase agonist | |
| JP7273110B2 (ja) | 高親和性抗ｖｅｇｆ抗体 | |
| JPWO2018175752A5 (enExample) | ||
| JP2022521428A (ja) | 抗炎症剤に連結されたｅｃｍ親和性ペプチドを用いて炎症性状態および自己免疫状態を処置するための方法および組成物 | |
| JP6925981B2 (ja) | Ｖｅｇｆとｎｒｐ１との結合を阻害する抗体 | |
| JP6449772B2 (ja) | ヒト抗ｖｅｇｆｒ２／ｋｄｒ抗体 | |
| TW201641515A (zh) | Ｖｅｇｆａ／ａｎｇ２化合物 | |
| ES2687183T3 (es) | Anticuerpos recombinantes contra el factor de crecimiento endotelial vascular (VEGF) que se obtienen mediante mutagénesis de regiones variables | |
| US20110129473A1 (en) | Vhnar anti-cytokine domains | |
| CN118240082A (zh) | Pd-1结合分子及其应用 | |
| US20220356236A1 (en) | Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules | |
| WO2011112850A2 (en) | Humanized and chimeric anti-properdin antibodies | |
| WO2016109943A1 (zh) | 抗vegf抗体 | |
| US10370442B2 (en) | vNAR recombinant monoclonal antibodies that neutralize vascular endophelial growth factor VEGF | |
| CA2868883A1 (en) | Fully human antibodies that bind to vegfr2 | |
| RU2019132064A (ru) | Оптимизированные композиции антител для лечения заболеваний глаз | |
| CN107531785B (zh) | 人抗-vegfr-2/kdr抗体 | |
| JPWO2022253314A5 (enExample) | ||
| WO2024078521A1 (zh) | 包含抗vegfr2抗体的制剂 | |
| JP6138304B2 (ja) | ＦＧＦＲ−Ｆｃ融合蛋白質およびその使用 | |
| RU2019133326A (ru) | Пролекарственные композиции на основе гидрогеля поперечно-сшитой гиалуроновой кислоты и способы |